Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Metrics to compare | MNPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNPRPeersSector | |
---|---|---|---|---|
P/E Ratio | −16.7x | −3.8x | −0.5x | |
PEG Ratio | 0.51 | 0.01 | 0.00 | |
Price/Book | 5.2x | 2.4x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.2x | |
Upside (Analyst Target) | 41.1% | 180.6% | 42.7% | |
Fair Value Upside | Unlock | 18.0% | 5.8% | Unlock |